PIK3CA and MTOR genes show gain-of-function mutations in about 2.5 and 6%, respectively, of renal tumors (COSMIC database), and the inhibition of the major effectors of the pathway (PI3K catalytic subunits, AKT, mTOR) is under intense exploration in clinical trials. The gene discussed is PIK3CA; the disease is Renal neoplasm.